ID   OVCAR-2
AC   CVCL_3941
SY   NIH:OVCAR-2; OVCAR2; OVCAR 2
DR   BTO; BTO:0002560
DR   cancercelllines; CVCL_3941
DR   GEO; GSM185133
DR   GEO; GSM185134
DR   GEO; GSM711707
DR   GEO; GSM851933
DR   GEO; GSM1340586
DR   GEO; GSM1341131
DR   Progenetix; CVCL_3941
DR   Wikidata; Q54937004
RX   PubMed=1348364;
RX   PubMed=2307530;
RX   PubMed=3930572;
RX   PubMed=6372095;
RX   PubMed=6385258;
RX   PubMed=9041185;
RX   PubMed=22710073;
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=22710073
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 13
ST   D18S51: 12,16
ST   D19S433: 13
ST   D21S11: 31
ST   D2S1338: 17,26
ST   D3S1358: 16
ST   D5S818: 11
ST   D7S820: 10
ST   D8S1179: 10,14
ST   FGA: 22
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C4908; Ovarian carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 17
//
RX   PubMed=1348364; DOI=10.1073/pnas.89.7.3070;
RA   Godwin A.K., Meister A., O'Dwyer P.J., Huang C.-S., Hamilton T.C.,
RA   Anderson M.E.;
RT   "High resistance to cisplatin in human ovarian cancer cell lines is
RT   associated with marked increase of glutathione synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992).
//
RX   PubMed=2307530; DOI=10.1002/ijc.2910450306;
RA   Schilder R.J., Hall L., Monks A., Handel L.M., Fornace A.J. Jr.,
RA   Ozols R.F., Fojo A.T., Hamilton T.C.;
RT   "Metallothionein gene expression and resistance to cisplatin in human
RT   ovarian cancer.";
RL   Int. J. Cancer 45:416-422(1990).
//
RX   PubMed=3930572; DOI=10.1172/JCI112082;
RA   Pirker R., FitzGerald D.J.P., Hamilton T.C., Ozols R.F., Laird W.J.,
RA   Frankel A.E., Willingham M.C., Pastan I.;
RT   "Characterization of immunotoxins active against ovarian cancer cell
RT   lines.";
RL   J. Clin. Invest. 76:1261-1267(1985).
//
RX   PubMed=6372095; DOI=10.1126/science.6372095;
RA   Rogan A.M., Hamilton T.C., Young R.C., Klecker R.W. Jr., Ozols R.F.;
RT   "Reversal of adriamycin resistance by verapamil in human ovarian
RT   cancer.";
RL   Science 224:994-996(1984).
//
RX   PubMed=6385258;
RA   Hamilton T.C., Young R.C., Ozols R.F.;
RT   "Experimental model systems of ovarian cancer: applications to the
RT   design and evaluation of new treatment approaches.";
RL   Semin. Oncol. 11:285-298(1984).
//
RX   PubMed=9041185;
RA   Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.;
RT   "Increased platinum-DNA damage tolerance is associated with cisplatin
RT   resistance and cross-resistance to various chemotherapeutic agents in
RT   unrelated human ovarian cancer cell lines.";
RL   Cancer Res. 57:850-856(1997).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//